Pyroglutamic Acidosis OVERVIEW Pyroglutamic acidosis is a rare cause of high anion gap metabolic acidosis (HAGMA) pyroglutamic acid is also known as 5-oxoprolinemia produced from -glutamyl cysteine by the enzyme -glutamyl cyclotransferase catabolised by 5-oxoprolinase when glutathione levels are low, the activity of -glutamyl cyclotransferase is increased, resulting in pyroglutamic acid accumulation in glutathione-depleted states CAUSE Risk factors elderly paracetamol use (glutathione depletion by its metabolite NAPQI) sepsis (depletion of glutathione) flucloxacillin (inhibits 5-oxoprolinase) hepatic and renal impairment malnutrition pregnancy vigabatrin congenital enzyme deficiencies (glutathione synthase deficiency) Pyroglutamic acidosis results from disruption of the -glutamyl cycle 5-oxoproline (aka pyroglutamic acid) is produced from -glutamyl cysteine by the enzyme -glutamyl cyclotransferase -glutamyl cyclotransferase activity increases when glutathione levels are low, due to a loss of feedback inhibition from glutathione accumulation of pyroglutamic acid is thought to be due to depletion of the glutathione, particularly when glutathione synthetase is inhibited Decreased activity of 5-oxoprolinase, which breaks down pyroglutamic acid, may also play a role CLINICAL FEATURES manifestations of acidaemia e.g
In these cases, hydroxocobalamin or adenosylcobalamin may be better tolerated, as they provide B12 support without strongly stimulating methylation
R., Roy, A
235 These findings provide evidence of increased ROS, decreased adiponectin, insulin resistance, and glucose intolerance due to adipocyte iron overload
30 demonstrated that the supplementation of leonurine to the maturation medium in bovine species decreased ROS levels and lipid content in oocytes, while increasing mitochondrial membrane potential and ATP content
In fact, some legal experts suggest that simply prescribing BPC-157 is malpractice per se, since its impossible to adequately inform a patient of risks that havent been studied
